domingo, 14 de marzo de 2010

Effectiveness of Recombinant Human Growth Hormone in the Treatment of Cystic Fibrosis



The Agency for Healthcare Research and Quality (AHRQ) Effective Health Care (EHC) Program is pleased to announce that the following draft research review is now available for public comment:

Effectiveness of Recombinant Human Growth Hormone in the Treatment of Cystic Fibrosis

This draft review examined the benefits and harms associated with using recombinant human growth hormone in patients with cystic fibrosis. It will be available for review and public comment on the EHC Program Web site until April 9, 2010. To review the draft, please visit:
http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/. See below:

Thank you,

Effective Health Care Program
www.effectivehealthcare.ahrq.gov



Research Available for Comment
The Effective Health Care Program [http://effectivehealthcare.ahrq.gov/index.cfm/what-is-the-effective-health-care-program1/]encourages the public to participate in the development of its research projects. Comments can be submitted for:

Research key questions. [http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/what-are-key-questions/]

Draft reports of research findings. [http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/what-is-a-draft-report/]

Draft methods reports by the DEcIDE Network. [http://effectivehealthcare.ahrq.gov/index.cfm/who-is-involved-in-the-effective-health-care-program1/about-the-decide-network/]

When key questions and draft reports of research projects are available for comment, they are posted on this Web page.

For timeliness, comments must be submitted during the 4-week period that the key questions and draft reports are posted on this Web page. The deadline for submission is 11:59 p.m. eastern time on the last day of the 4-week submission period.

If you would like to be notified when new key questions or draft reports are available for comment, please join the EHC Program e-mail list [http://effectivehealthcare.ahrq.gov/index.cfm/join-the-email-list1/].

The Key Questions available for comment are:
1. Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis - Update
Feb. 19–Mar. 19, 2010
http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/?pageaction=displayquestions&topicid=160&questionset=111

2. Comparative Effectiveness of Adjunctive Devices To Remove Thrombus and/or Protect from Distal Embolization in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention of Native Vessels
Feb. 19–Mar. 19, 2010
http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/?pageaction=displayquestions&topicid=162&questionset=112

3. Comparative Effectiveness Screening, Monitoring and Treatment of Early Chronic Kidney Disease in Adults
Feb. 26–Mar. 26, 2010
http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/?pageaction=displayquestions&topicid=163&questionset=113

The Draft Reports available for comment are:
Registries for Evaluating Patient Outcomes: A User’s Guide: 2nd Edition
Mar. 3–31, 2010
http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/comment-draft-reports/?pageaction=displaydraftcommentform&topicid=74&productid=402&documenttype=draftReport

Effectiveness of Recombinant Human Growth Hormone in the Treatment of Cystic Fibrosis
Mar. 12–Apr. 9, 2010
http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/comment-draft-reports/?pageaction=displaydraftcommentform&topicid=98&productid=414&documenttype=draftReport

Privacy Policy
The Agency for Healthcare Research and Quality supports and is committed to the transparency of its review processes. Therefore, the following are posted on the EHC Program Web site within 3 months after a final report is posted: 1) all comments received from the public, and 2) all the responses made by the authors of a draft report to the public comments (i.e., the “disposition of comments”). Each comment will be listed with the name and affiliation of the commentator, if such information is provided. Public commentators are not required to provide their names or affiliations to submit suggestions or comments. Contact information will be used to communicate with commentators if there are questions about submitted comments.

Related Content

What Is a Draft Report? http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/what-is-a-draft-report/

What Are Key Questions?
http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/what-are-key-questions/

open here please:
http://effectivehealthcare.ahrq.gov/index.cfm/research-available-for-comment/

No hay comentarios:

Publicar un comentario